Peters, S. Danson, S. Hasan, B. Dafni, U. Reinmuth, N. Majem, M. Tournoy, K.G. Mark, M.T. Pless, M. Cobo, M. Rodriguez-Abreu, D. Falchero, L. Moran, T. Ortega Granados, A.L. Monnet, I. Mohorcic, K. Sureda, B.M. Betticher, D. Demedts, I. Macias, J.A. Cuffe, S. Luciani, A. Sanchez, J.G. Curioni-Fontecedro, A. Gautschi, O. Price, G. Coate, L. von Moos, R. Zielinski, C. Provencio, M. Menis, J. Ruepp, B. Pochesci, A. Roschitzki-Voser, H. Besse, B. Rabaglio, M. O'Brien, M.E.R. Stahel, R.A., A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial, Journal of Thoracic Oncology, (15), 1647-1656, 2020, HANLEY & BELFUS-ELSEVIER INC, 1556-0864, 1556-1380